Your browser doesn't support javascript.
loading
[Annual progress in treatment of bronchial asthma 2022].
Huang, H Q; Shen, H H.
Afiliación
  • Huang HQ; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
  • Shen HH; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
Zhonghua Jie He He Hu Xi Za Zhi ; 46(1): 55-61, 2023 Jan 12.
Article en Zh | MEDLINE | ID: mdl-36617930
ABSTRACT
Bronchial asthma is one of the most common chronic inflammatory airway diseases. Its incidence is increasing annually worldwide, posing a heavy medical burden to society and individuals. At the same time, continuous improvement has been made in the diagnosis and treatment strategies of asthma. With the advancement of basic research and the emergence of evidence-based evidence on asthma, new drugs, updated ideas and strategies have appeared in the field of asthma treatment. This article reviewed the progress and achievements in the field of asthma treatment from 1st October 2021 to 30th September 2022, as well as several updated guidelines and consensus guidance on asthma, providing clinical perspective for the treatment of asthma.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: Zh Revista: Zhonghua Jie He He Hu Xi Za Zhi Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: Zh Revista: Zhonghua Jie He He Hu Xi Za Zhi Año: 2023 Tipo del documento: Article País de afiliación: China